비교리스트

 카트 문의
시장보고서
상품코드
1374769

세계의 한랭응집소병 치료 시장(2023-2030년)

Global Cold Agglutinin Disease Treatment Market - 2023-2030
발행일: | 리서치사: DataM Intelligence | 페이지 정보: 영문 186 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

개요

세계 한랭응집소병 치료제 시장은 다양한 요인으로 인해 수년간 괄목할 만한 성장과 변화를 겪어왔습니다. 희귀한 종류의 자가면역성 용혈성 빈혈은 한랭응집소병으로 알려져 있으며, 추위에 반응하는 자가 항체에 의해 발생합니다.

특히 신흥 경제국의 정부 투자와 연구 개발은 앞으로도 첨단 치료법의 사용을 촉진하여 세계 한랭응집소병 치료제 시장을 견인할 것으로 보입니다. 각각의 혁신적인 치료법에는 더 나은 치료를 위해 단일 클론 항체를 사용하는 것이 포함됩니다.

시장 역학 : 촉진요인

신규 치료법 또는 약품 개발 확대

신흥 경제 국가들은 높은 소득 수준, 투자, 인프라 구축에 힘입어 헬스케어 분야가 빠르게 성장하고 있습니다. 일부 국가에서는 임상시험에서 좋은 결과를 얻고 의약품으로 승인되면서 한랭응집소병 치료에 대한 수요가 증가하고 있습니다.

2023년 7월 7일, 사노피의 임상시험용 약물 SAR445088은 CAD 세포 모델에서 적혈구 손상이 적고 한랭응집소병(CAD)과 관련된 면역 체계의 구성요소인 기존 보체 경로를 억제하는 데 성공했으며, SAR445088은 보다 집중적인 작용을 통해 사노피의 Enjaymo(sutimlimab-jome)를 대체할 가능성이 있습니다. 성인 CAD 환자를 대상으로 유럽에서 임상 1상 시험(NCT04802057)이 진행 중입니다. 사람들의 인식이 높아지고 3상 시험 단계에 있는 약물을 포함한 강력한 파이프라인의 증가는 한랭 응집 증후군 치료제 시장의 성장을 촉진하는 주요 요인이 될 것입니다.

시장 역학: 시장 억제요인

약물에 따른 부작용

증상성 빈혈 및 기타 골치 아픈 증상이 있는 환자에게는 치료가 필요하지만 약물 치료가 반드시 필요한 것은 아닙니다. 부신피질 스테로이드는 부작용으로 인해 CAD 치료에 권장되지 않습니다. 부정맥, 심장마비, 심인성 쇼크와 같은 심장 및 심장 리듬 문제는 이 약물로 인해 발생할 수 있으며, mAbs를 투여하면 혈청 질환, 급성 아나필락시스, 항체 생산과 같은 면역학적인 반응이 발생할 수 있습니다.

본 보고서에 대한 자세한 내용 - 샘플 요청

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

  • 영향요인
    • 성장 촉진요인
      • 신규 치료법이나 신약의 개발
      • 기술적 진보 상승
    • 성장 억제요인
      • 약제에 따른 부작용
    • 기회
    • 영향 분석

제5장 산업 분석

  • Porter's Five Forces 분석
  • 공급망 분석
  • 가격 분석
  • 규제 분석
  • 가격 분석
  • SWOT 분석
  • 특허 분석
  • 러시아·우크라이나 전쟁의 영향 분석
  • DMI 의견

제6장 COVID-19 분석

제7장 유형별

  • 1차성 한랭응집소병
  • 2차성 한랭응집소병

제8장 약제 유형별

  • 생물학적 제제
    • Sutimlimab (Enjaymo)
    • Rituximab (Rituxan)
    • Eculizumab (Soliris)
  • 푸린 아날로그
    • Fludarabine
    • Azathioprine
  • 코르티코스테로이드
    • Prednisone
  • 알킬화제
    • Chlorambucil
    • Cyclophosphamide
  • 엽산 보충제
  • 기타

제9장 투여 경로별

  • 경구
  • 비경구

제10장 유통 채널별

  • 병원 약국
  • 소매 약국
  • 온라인 약국

제11장 지역별

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 남미
    • 브라질
    • 아르헨티나
    • 기타 남미
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카

제12장 경쟁 상황

  • 경쟁 시나리오
  • 시장 상황/점유율 분석
  • M&A 분석

제13장 기업 개요

  • Sanofi
    • 기업 개요
    • 제품 포트폴리오와 설명
    • 재무 개요
    • 주요 발전
  • NovelMed Inc.
  • Novartis AG
  • Swedish Orphan Biovitrum AB
  • Apellis Pharmaceuticals, Inc.
  • Alpine Immune Sciences
  • Genentech USA, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Viatris Inc.

제14장 부록

ksm 23.11.13

Overview

The global cold agglutinin disease treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A uncommon kind of autoimmune hemolytic anemia is known as cold agglutinin disease, which is brought on by autoantibodies that react to cold.

Government investments and research, particularly in developing economies, will continue to drive utilization of advanced treatments and boost the global cold agglutinin disease treatment market. The respective innovative treatments includes the use of monoclonal antibodies for better treatment.

Market Dynamics: Drivers

Growing development of novel therapies or drugs

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high income levels, investments and infrastructure development. Several countries have experienced substantial demand for cold agglutinin disease treatment owing to its positive outcomes in clinical trials leading to drug approval will be a crucial factor driving the growth of the market.

On July 7, 2023, with less red blood cell damage in a cellular model of CAD, Sanofi's investigational medication SAR445088 successfully inhibits the traditional complement pathway, a component of the immune system linked to cold agglutinin disease (CAD) in a study. Because of its more focused activity, SAR445088 might replace Sanofi's Enjaymo (sutimlimab-jome). Adults with CAD are being investigated with the next-generation treatment in a Phase 1 clinical trial in Europe (NCT04802057). Rising awareness among people and increasing robust pipeline with drugs in phase 3 will be a major factor driving the growth of the cold agglutinin syndrome drugs market.

Market Dynamics: Restraints

Side effects associated with the drugs

Patients having symptomatic anemia or other annoying symptoms should be addressed, while medication is not always necessary. Due to their negative effects, corticosteroids are not recommended to treat CAD. Heart or heart rhythm issues, such as arrhythmia, heart attacks, and cardiogenic shock, could be brought on by this medication. When mAbs are administered, there is a chance of immunological reactions like serum sickness, acute anaphylaxis, and the production of antibodies.

For more details on this report - Request for Sample

Segment Analysis

The global cold agglutinin disease treatment market is segmented based on type, drug type, route of administration, distribution channel and region.

Biologics segment holds approximately 37% of market share

The biologics segment from drug type is the largest share holder among all the drug types owing to its high effectiveness and rising researches and product developments. Monoclonal antibodies, immune modulators, growth factors, vaccinations, and items made from human blood and plasma all fall within the broad category of biological medicines.

Rituximab, a monoclonal antibody, is the first- and second-line treatment for cold agglutinin illness as well as the preferred therapy for steroid-refractory warm autoimmune hemolytic anemia (wAIHA).

Geographical Penetration

North America accounted for around 33% of market share in 2022

Due to the rising need for cold agglutinin disease treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for cold agglutinin disease treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different type of drugs for treatment, and increase in pharmaceutical or biotech business establishment across the region are also contributing to the growth of cold agglutinin disease treatment market share of this region. The market in this area is growing as people become more aware of various novel treatments such as monoclonal antibodies. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global cold agglutinin disease treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for cold agglutinin disease treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating cold agglutinin disease treatment drugs demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global cold agglutinin disease treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various types of drugs, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for cold agglutinin disease treatment. Now several research studies have been initiated and companies have again started trial for their respective pipelines. Overall, the impact of the pandemic on the global cold agglutinin disease treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for monoclonal antibodies and other programs to control such kind of disorders.

Key Developments

  • On February 4, 2022, Enjaymo (sutimlimab-jome) has received FDA approval to reduce the requirement for red blood cell transfusions in adults having cold agglutinin disease (CAD) related to hemolysis. Enjaymo, the first and only medication for CAD to receive FDA approval, prevents the breakdown of red blood cells (hemolysis).

Competitive Landscape

The major global players in the market include: Sanofi, NovelMed Inc., Novartis AG, Swedish Orphan Biovitrum AB, Apellis Pharmaceuticals, Inc., Alpine Immune Sciences, Genentech USA, Inc., Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc. and Viatris Inc. among others.

Why Purchase the Report?

  • To visualize the global cold agglutinin disease treatment market segmentation based on type, drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cold agglutinin disease treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global cold agglutinin disease treatment market report would provide approximately 69 tables, 68 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing development of novel therapies or drugs
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pricing Analysis
  • 5.6. SWOT Analysis
  • 5.7. Patent Analysis
  • 5.8. Russia-Ukraine War Impact Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Primary Cold Agglutinin Disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Secondary Cold Agglutinin Disease

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Biologics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Sutimlimab (Enjaymo)
    • 8.2.4. Rituximab (Rituxan)
    • 8.2.5. Eculizumab (Soliris)
  • 8.3. Purine Analogue
    • 8.3.1. Fludarabine
    • 8.3.2. Azathioprine
  • 8.4. Corticosteroid
    • 8.4.1. Prednisone
  • 8.5. Alkylating Agents
    • 8.5.1. Chlorambucil
    • 8.5.2. Cyclophosphamide
  • 8.6. Folic Acid Supplements
  • 8.7. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Sanofi*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. NovelMed Inc.
  • 13.3. Novartis AG
  • 13.4. Swedish Orphan Biovitrum AB
  • 13.5. Apellis Pharmaceuticals, Inc.
  • 13.6. Alpine Immune Sciences
  • 13.7. Genentech USA, Inc.
  • 13.8. Alexion Pharmaceuticals, Inc.
  • 13.9. Teva Pharmaceuticals USA, Inc.
  • 13.10. Viatris Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제